Childhood Cancer Data Initiative Annual Symposium (Abstract Registration): Submission #51

Submission information
Submission Number: 51
Submission ID: 150209
Submission UUID: cc99a1f0-11db-47d8-b23b-91b9f1762bb4

Created: Fri, 08/29/2025 - 11:20
Completed: Fri, 08/29/2025 - 11:28
Changed: Fri, 08/29/2025 - 11:28

Remote IP address: 10.208.24.168
Submitted by: Anonymous
Language: English

Is draft: No
Abstract Title: Characterizing the Children’s Oncology Group panel of neuroblastoma patient-derived xenografts for response to induction and salvage chemotherapy
Abstract: Tumor biopsies are often not obtained at the time of progressive disease (PD) in neuroblastoma (NB). Patient-derived xenografts (PDXs) established from bone marrow or blood of NB patients enable studies to define molecular mechanisms and approaches to overcome therapy resistance. Tumor, marrow, or peripheral blood samples from 40 high-risk patients, 19 at diagnosis (Dx) and 21 at PD (12 of 21 at post-mortem), were received via Children’s Oncology Group (COG) protocol ANBL00B1 and established as PDXs. PDXs were classified by the response to chemotherapy (Cyclo/Topo, cyclophosphamide + topotecan, 3 x 21 day-cycles or TMZ/IRI, relapse chemo, temozolomide + irinotecan, 2 x 21 day-cycles) as non-responders (NR), stable disease (SD), partial responders (PR) and complete responders (CR). Engraftment rates were 17% for Dx and 24% for PD samples. Based on an algorithm we developed for PDX response evaluation, Cyclo/Topo response was: NR (n=11), SD (n=2), PR (n=9), and CR (n=18) while nine of 11 showed CR to TMZ/IRN. Nine of 13 (69%) of the NR+SD PDXs were established from post-mortem PD (PD-PM) samples while 12 of 18 (67%) of the CR group were from Dx samples. The response of PDXs to Cyclo/Topo was greater for pretherapy (Dx) PDXs than PD-PM or PD PDXs; six of the 11 PD models showed significantly better EFS for TMZ/IRN relative to Cyclo/Topo (P<0.05, n=6 PDXs). This panel of 40 NB PDXs, characterized for their response to chemotherapy, will enable studies to define the molecular mechanisms of NB therapy resistance and is available at www.CCcells.org.
Abstract:
Authors:
  1. First Name: Min
    Middle Initial: H
    Last Name: Kang
    Degree(s): PharmD
    Organization: Texas Tech University Health Sciences Center
  2. First Name: In-Hyoung
    Last Name: Yang
    Degree(s): PhD
    Organization: Texas Tech University Health Sciences Center
  3. First Name: Kristyn
    Last Name: McCoy
    Degree(s): MS
    Organization: Texas Tech University Health Sciences Center
  4. First Name: Jonas
    Last Name: Nance
    Degree(s): BS
    Organization: Texas Tech University Health Sciences Center
  5. First Name: Diana
    Last Name: Ixlamati-Nava
    Degree(s): BS
    Organization: Texas Tech University Health Sciences Center
  6. First Name: Nighat
    Last Name: Noureen
    Degree(s): PhD
    Organization: Texas Tech University Health Sciences Center
  7. First Name: Ashly
    Last Name: Hindle
    Degree(s): PhD
    Organization: Texas Tech University Health Sciences Center
  8. First Name: Meredith
    Middle Initial: S
    Last Name: Irwin
    Degree(s): MD
    Organization: Hospital for Sick Children, University of Toronto
  9. First Name: Michael
    Middle Initial: D
    Last Name: Hogarty
    Degree(s): MD
    Organization: Children's Hospital of Philadelphia, University of Pennsylvania
  10. First Name: Charles
    Middle Initial: P
    Last Name: Reynolds
    Degree(s): MD, PhD
    Organization: Texas Tech University Health Sciences Center
Presenting Author: Min H. Kang
Institution: Texas Tech University Health Sciences Center
Email Address: min.kang@ttuhsc.edu